Among these, NPT1, NPT4, OAT1, OAT2, OAT3, and ABCG2 are associated with UA secretion [15, 16], and OAT4, OAT10, URAT1, and GLUT9 are closely related to UA reabsorption [14](Fig
What 5 mg Tirzepatide Does Across the obesity trials, 5 mg per week is already a remarkably effective dose: Mean weight loss at 72 weeks of 15% from baseline body weight, compared with 3% on placebo Roughly 85% of people lose at least 5% of body weight at 5 mg, versus 35% on placebo HbA1c reduction in diabetes trials of about 1.9 percentage points from baseline at 5 mg A 31 to 52% rate of reaching HbA1c below 5.7%, the prediabetes-to-normal threshold Compared head-to-head with semaglutide 1 mg (the standard dose for the comparator drug at the time), tirzepatide 5 mg led to 1.9 kg more weight loss and a 0.15-percentage-point greater HbA1c reduction in a Phase 3 trial of 1,879 patients
Cardiovascular Applications TB-500 has demonstrated significant cardiovascular benefits in preclinical investigations, particularly in models of myocardial injury and cardiac remodeling
Badenhorst T, Svirskis D, Merber M, Wu Z